Parkinson-like wild-type superoxide dismutase 1 pathology induces nigral dopamine neuron degeneration in a novel murine model
Acta Neuropathologica · 05.03.2025 · 149 (1)
DOI: 10.1007/s00401-025-02859-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 05.03.2025. Verfasst von Amr H Abdeen und 29 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Mind Centre and School of Medical Sciences (Neuroscience), Faculty of Medicine and Health, The University of Sydney, 94-100 Mallett Street,…. Hauptthemen laut MEDLINE: Superoxide Dismutase-1, Dopaminergic Neurons, Parkinson Disease, Substantia Nigra. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council,Australia, Michael J. Fox Foundation for Parkinson's Research, Australian Research Council,Australia.
Abstract (Originalsprache)
Atypical wild-type superoxide dismutase 1 (SOD1) protein misfolding and deposition occurs specifically within the degenerating substantia nigra pars compacta (SNc) in Parkinson disease. Mechanisms driving the formation of this pathology and relationship with SNc dopamine neuron health are yet to be fully understood. We applied proteomic mass spectrometry and synchrotron-based biometal quantification to post-mortem brain tissues from the SNc of Parkinson disease patients and age-matched controls to uncover key factors underlying the formation of wild-type SOD1 pathology in this disorder. We also engineered two of these factors - brain copper deficiency and upregulated SOD1 protein levels - into a novel mouse strain, termed the SOCK mouse, to verify their involvement in the development of Parkinson-like wild-type SOD1 pathology and their impact on dopamine neuron health. Soluble SOD1 protein in the degenerating Parkinson disease SNc exhibited altered post-translational modifications, which may underlie changes to the enzymatic activity and aggregation of the protein in this region. These include decreased copper binding, dysregulation of physiological glycosylation, and atypical oxidation and glycation of key SOD1 amino acid residues. We demonstrated that the biochemical profile introduced in SOCK mice promotes the same post-translational modifications and the development of Parkinson-like wild-type SOD1 pathology in the midbrain and cortex. This pathology accumulates progressively with age and is accompanied by nigrostriatal degeneration and dysfunction, which occur in the absence of α-synuclein deposition. These mice do not exhibit weight loss nor spinal cord motor neuron degeneration, distinguishing them from transgenic mutant SOD1 mouse models. This study provides the first in vivo evidence that mismetallation and altered post-translational modifications precipitates wild-type SOD1 misfolding, dysfunction, and deposition in the Parkinson disease brain, which may contribute to SNc dopamine neuron degeneration. Our data position this pathology as a novel drug target for this disorder, with a particular focus on therapies capable of correcting alterations to SOD1 post-translational modifications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain and Mind Centre and School of Medical Sciences (Neuroscience), Faculty of Medicine and Health, The University of Sydney, 94-100 Mallett Street, Camperdown, Sydney, NSW, 2006, Australia.
- Department of Anatomy & Physiology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, 3052, Australia.
- Sydney Microscopy and Microanalysis, The University of Sydney, Sydney, NSW, 2006, Australia.
- Univ. Bordeaux, CNRS, LP2I Bordeaux, UMR 5797, 33170, Gradignan, France.
- Mass Spectrometry Facility, Faculty of Science, The University of Sydney, Sydney, NSW, 2006, Australia.
- Deutsches Elektronen-Synchrotron DESY, Notkestr. 85, 22607, Hamburg, Germany.
Förderung
- National Health and Medical Research Council,Australia
- Michael J. Fox Foundation for Parkinson's Research
- Australian Research Council,Australia
- Association France Parkinson
- University of Sydney
Zitieren
APA
Abdeen, A. H., Trist, B. G., Nikseresht, S., Harwood, R., Roudeau, S., Rowlands, B. D., Kreilaus, F., Cottam, V., Mor, D., Richardson, M., Siciliano, J., Forkgen, J., Schaffer, G., Genoud, S., Li, A. A., Proschogo, N., Antonio, B., Falkenberg, G., Brueckner, D., …, & Double, K. L. (2025). Parkinson-like wild-type superoxide dismutase 1 pathology induces nigral dopamine neuron degeneration in a novel murine model. Acta Neuropathologica, 149(1). https://doi.org/10.1007/s00401-025-02859-6
Vancouver
Abdeen AH, Trist BG, Nikseresht S, Harwood R, Roudeau S, Rowlands BD, et al. Parkinson-like wild-type superoxide dismutase 1 pathology induces nigral dopamine neuron degeneration in a novel murine model. Acta Neuropathologica. 2025;149(1). doi:10.1007/s00401-025-02859-6
BibTeX
@article{Abdeen2025,
author = {Abdeen, Amr H and Trist, Benjamin G and Nikseresht, Sara and Harwood, Richard and Roudeau, Stéphane and Rowlands, Benjamin D and Kreilaus, Fabian and Cottam, Veronica and Mor, David and Richardson, Miriam and Siciliano, Joel and Forkgen, Julia and Schaffer, Greta and Genoud, Sian and Li, Anne A and Proschogo, Nicholas and Antonio, Bernadeth and Falkenberg, Gerald and Brueckner, Dennis and Kysenius, Kai and Liddell, Jeffrey R and Fat, Sandrine Chan Moi and Wu, Sharlynn and Fifita, Jennifer and Lockwood, Thomas E and Bishop, David P and Blair, Ian and Ortega, Richard and Crouch, Peter J and Double, Kay L},
title = {Parkinson-like wild-type superoxide dismutase 1 pathology induces nigral dopamine neuron degeneration in a novel murine model},
journal = {Acta Neuropathologica},
year = {2025},
volume = {149},
number = {1},
doi = {10.1007/s00401-025-02859-6}
}
EUVIMED